Key result
Prescribing non-recommended, unreasonably low doses of direct oral anticoagulants in patients with atrial fibrillation may increase the risk of adverse clinical outcomes, including mortality, without further reducing bleeding risk.
Why the study?
Non-recommended low dosing of direct oral anticoagulants is frequently used in clinical practice despite the need to provide maximum anticoagulant efficiency in atrial fibrillation.
Does the use of non-recommended low doses of direct oral anticoagulants affect the risk of adverse clinical outcomes in patients with atrial fibrillation?
Does the use of non-recommended low doses of direct oral anticoagulants affect the risk of adverse clinical outcomes in patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Inappropriate under-dosing of direct oral anticoagulants in atrial fibrillation may reduce efficacy without meaningfully improving safety, highlighting the importance of adhering to guideline-recommended dosing.
The article presents updated information on the frequency of use of non-recommended low dosing of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). It gives substantiation of the urgency of the issue of providing the maximum efficiency of the use of anticoagulants in clinical practice, taking into account the high prevalence of atrial fibrillation and the pharmacological characteristics of the most commonly used drugs. The effects of such an unreasonable reduction in anticoagulant doses in elderly and senile patients are discussed. The results of recent observational studies that assessed the relationship between the use of direct oral anticoagulants and the risk of adverse clinical outcomes are presented. The data on the relationship between the use of unreasonably low dosing of anticoagulants in patients with atrial fibrillation, which were recently obtained during the implementation of the GARFIELD-AF registry, are discussed. The data on a rather high variability of concentrations of direct oral anticoagulants are presented. The frequency of using apixaban in an unreasonably reduced dose, as well as the effects of using non-recommended doses of apixaban hold a specific place in the article. The unreasonableness of attempts to further reduce the risk of bleeding due to unreasonable reduction of apixaban dosing is emphasized, taking into account the stable data on the high safety of recommended dosing of apixaban, as well as the possible decrease in the effect if the dose reduction is not recommended. The data on the criteria for dose reduction, which are adopted in different countries, are presented. The proposed terms to designate different doses of direct oral anticoagulants, depending on their study in the course of large, randomized trials are discussed.
No takes yet. Share an insight, caveat, or question.
Gilyarevskiy et al. (2021) conducted a review in Atrial fibrillation. Non-recommended low doses of direct oral anticoagulants vs. Recommended doses of direct oral anticoagulants was evaluated. Prescribing non-recommended, unreasonably low doses of direct oral anticoagulants in patients with atrial fibrillation may increase the risk of adverse clinical outcomes, including mortality, without further reducing bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: